EXPERTS WARN NORTHERN IRELAND RISKS BEING LEFT BEHIND ON LIFE-SAVING LUNG CANCER SCREENING


Hillsborough Castle meeting as specialists call for action

Belfast, 19 November 2026: Northern Ireland risks being left behind as the rest of the UK moves ahead with life-saving lung cancer screening, leading experts will warn today. 

The call comes as clinicians, healthcare leaders and patient representatives gather at Hillsborough Castle for the Northern Ireland Lung Cancer Meeting, on behalf of the Ulster Thoracic Society and supported by the UK Lung Cancer Coalition (UKLCC).1

“Lung cancer is Northern Ireland’s biggest cancer killer,” says Dr Wendy Anderson, Respiratory Physician, Chair of the Lung Cancer Clinical Reference Group in Northern Ireland and spokesperson for the Ulster Thoracic Society. “Despite the UK National Screening Committee recommending targeted lung cancer screening in 2022, Northern Ireland remains the only UK nation without a screening programme or public commitment to introduce one.”

In England, more than two million people aged 55 to 74 with a history of smoking have already attended a lung cancer screening appointment. Nearly 13,000 lung cancers have been detected as a result, with around three-quarters found at an early stage.2 Wales is well-advanced in its plans for a national programme, while Scotland has completed a major pilot.3,4

"Northern Ireland has a real opportunity to transform lung cancer outcomes. We know that finding lung cancer earlier via screening gives people access to more treatment options and a far greater chance of survival. It is vital that Northern Ireland does not fall further behind the rest of the UK," adds Dr Anderson.

More than 1,000 people die from lung cancer in Northern Ireland each year, and almost half of patients (44.6%) are diagnosed at stage IV, when curative treatment is rarely possible.5 Currently, only 15.9% of lung cancer patients in Northern Ireland will survive five years after diagnosis, the lowest of the UK nations.6 However, experts estimate that around four in five (79%) lung cancer cases are preventable.7  The UKNSC therefore recommended that smoking cessation programmes should be firmly embedded in all UK targeted lung cancer screening programmes.8

"People in Northern Ireland should not have to wait longer for access to a service that is already benefiting patients elsewhere in the UK," says Cathy Brokenshire, lung cancer campaigner, a director of the UKLCC and widow of former Northern Ireland Secretary, the Rt Hon James Brokenshire MP, who died from lung cancer.

Major international studies have shown that lung cancer screening can successfully reach people at highest risk of the disease, including those living in deprived and rural communities, while delivering good value for healthcare systems.9,10

"As part of James's legacy, I am determined to keep lung cancer screening high on the political agenda and ensure that no family faces the devastating consequences of a late diagnosis, whoever they are and wherever they live. Earlier detection saves lives."

Alongside screening, delegates at the Hillsborough Castle meeting will review progress on wider priorities for lung cancer services, including stop smoking services, tackling the health inequalities, improving access to diagnostics and treatment, and delivering the commitments set out in the Blueprint for Lung Cancer in Northern Ireland report, published earlier this year on the UKLCC’s website: www.uklcc.org.uk

-ends-

About lung cancer screening:
•    The first large study which showed that lung cancer screening works (the National Lung Cancer Screening Trial) was published in 2011.9
•    If a screening programme had been implemented at that time, it is estimated that at least 17,000 UK lives would have been saved within 10 years. 11

About the Ulster Thoracic Society
The Ulster Thoracic Society is a health professional organisation for clinicians, researchers, and healthcare professionals involved in respiratory medicine in Northern Ireland. Its primary aim is to support education, professional development, and the sharing of best practices in the diagnosis, treatment, and management of respiratory diseases.

About the UKLCC
The UKLCC is the UK’s largest multi-interest group in lung cancer. It was set up in 2005 with the founding ambition to tackle poor lung cancer survival outcomes and, specifically, to double five-year survival by 2015, which was achieved. It recently launched its new five-year survival ambition, 35 by 35: 35 percent of people alive five years after diagnosis by 2035. The UKLCC’s membership includes leading lung cancer experts, senior NHS professionals, charities, and healthcare companies with an interest in fighting lung cancer. For more information about its work and members, visit: www.uklcc.org.uk

References:
1.    Northern Ireland Lung Cancer Meeting, Hillsborough Castle, 19th November 2026 
2.    NHSE Monthly Lung Cancer Screening Newsletter dated 16 October 2026. Data from April 2019 to July 2026.
3.    Cabinet Statement, Welsh Assembly 28th June 2025. A National Lung Screening Programme for Wales. Accessed October 2026: https://www.gov.wales/written-statement-national-lung-screening-programme-wales
4.    Pilot feasibility study to deliver low-dose CT lung cancer screening in Scotland: descriptive findings from the LUNGSCOT study. Cavers D et al. Accessed October 2026:  https://bmjopen.bmj.com/content/16/9/e120569
5.    NI Cancer Registry: Lung Cancer Statistics 1993-2023. Accessed October 2026: https://www.qub.ac.uk/research-centres/nicr/file-store/OfficialStats1993-2023/Lung%20cancer%20report.pdf
6.    Cancer Research UK- Cancer survival by UK country and cancer, 5-year survival. Accessed October 2026:  https://crukcancerintelligence.shinyapps.io/CancerStatsDataHub/_w_6396e5a5b203438e89df031604d4adac/?_inputs_&nav=%22Survival%20By%20UK%20Country%20and%20Cancer%20Site%22&Survival-select_CountrySurvCommon=%22Northern%20Ireland%22&Survival-select_CountrySurvGender=%22Northern%20Ireland%22&Survival-select_CountrySurvAge=%22Northern%20Ireland%22&Survival-select_CountrySurvDep=%22%22&Survival-select_CancerSiteSurvGender=%22Lung%22&Survival-select_CancerSiteSurvAge=%22Lung%22&Survival-select_CancerSiteSurvDep=%22%22
7.    Cancer Research UK Lung Cancer Statistics Lung Cancer Risk. Accessed October 2026: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer
8.    UK National Screening Committee Recommendation June 2022. Accessed October 2026: https://view-health-screening-recommendations.service.gov.uk/lung-cancer/
9.    Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. The National Lung Screening Trial Research Team, New England Journal of Medicine, August 2011. Accessed here October 2026: https://www.nejm.org/doi/full/10.1056/NEJMoa1102873
10.    Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. De Koning et al, J New England Journal of Medicine, January 2020. Accessed October 2026: https://www.nejm.org/doi/full/10.1056/NEJMoa1911793?referrer=https%3A%2F%2Fwww.bing.com%2F
11.    Changing the odds: A Briefing on Lung Cancer Screening in England, Roy Castle Lung Cancer Foundation. Accessed October 2026: https://roycastle.org/about-us/campaigns/changing-the-odds/changing-the-odds-a-briefing-on-lung-cancer-screening-in-england/

  1.  

Media Enquiries

For media enquiries, please contact:

Lynsey Conway, UKLCC Communications Consultant
07778 304233 or external-affairs@uklcc.org.uk